Labetalol HCl is an adrenergic receptor blocking agent that has both selective alpha1- and nonselective beta-adrenergic receptor blocking actions in a single substance.
Labetalol HCl Injection is indicated for control of blood pressure in severe hypertension.
Published Studies Related to Labetalol
Changes in fetal and maternal Doppler parameters observed during acute severe hypertension treatment with hydralazine or labetalol: a randomized controlled trial. [2011.01]
We evaluated 16 pregnant women with gestational age between 20 and 32 weeks in acute severe hypertension which were randomly allocated to receive either hydralazine or labetalol. Blood pressure and Doppler ultrasound parameters from maternal uterine and fetal middle cerebral and umbilical arteries were assessed during acute severe hypertension and after treatment...
CLUE: a randomized comparative effectiveness trial of IV nicardipine versus labetalol use in the emergency department. 
INTRODUCTION: Our purpose was to compare the safety and efficacy of food and drug administration (FDA) recommended dosing of IV nicardipine versus IV labetalol for the management of acute hypertension... CONCLUSIONS: Patients treated with nicardipine are more likely to reach the physician-specified SBP target range within 30 minutes than those treated with labetalol.
Benzodiazepine and opioid sedation attenuate the sympathetic response to fiberoptic bronchoscopy. Prophylactic labetalol gave no additional benefit. Results of a randomized double-blind placebo-controlled study. [2008.07]
BACKGROUND: Hypertension and tachycardia are common during fiber-optic bronchoscopy (FOB), and this may lead to cardiac ischemia. The prophylactic addition of a beta-adrenergic anatagonist might mask this response and prevent the deleterious cardiovascular effects of FOB... CONCLUSIONS: Patients undergoing FOB under adequate midazolam-alfentanil sedation do not develop excessive sympathetic drive that may lead to cardiac stress. The addition of labetalol did not confer additional benefit or risk to the patients. (ClinicalTrials.gov number, NCT00394537).
Severe hypertension in pregnancy: hydralazine or labetalol. A randomized clinical trial. [2006.09]
OBJECTIVE: The objective was to compare the safety and efficacy of intravenous labetalol and intravenous hydralazine for acutely lowering blood pressure in pregnancy... CONCLUSIONS: This randomized clinical trial shows that labetalol and hydralazine fulfill the criteria required for an antihypertensive drug to treat severe hypertension in pregnancy.
Pharmacokinetic interaction studies of atosiban with labetalol or betamethasone in healthy female volunteers. [2005.11]
OBJECTIVES: In two separate trials, we studied the concomitant administration of atosiban with labetalol and betamethasone to determine any possibility of a clinically relevant pharmacokinetic interaction. DESIGN: Study 1 was an open-label, single dose atosiban, multiple dose labetalol, interaction study. Study 2 was an open-label, randomised, three-period crossover pharmacokinetic study. SETTING: The studies were carried out at the Clinical Pharmacology Unit of AAI Deutschland GmbH & Co KG, Neu-Ulm, Germany. POPULATION: The study population consisted of healthy female volunteers... CONCLUSION: The co-administration of atosiban with betamethasone or labetalol had no clinically relevant influence on their bioavailability or tolerability.
Clinical Trials Related to Labetalol
Hydralazine Versus Labetalol for the Management of Hypertensive Disorders of Pregnancy [Recruiting]
Hypertensive crisis (defined as a systolic pressure > 160mmHg or a diastolic pressure >
110mmHg) in patients with a hypertensive disorder of pregnancy is a serious complication
with severe and even deadly consequences. The management in this population had been
studied, but no consensus has been reached with regards to which treatment is better. Our
study will compare two drugs: Hydralazine and Labetalol for the management of hypertensive
Labetalol Versus Magnesium Sulfate (MgSO4) for the Prevention of Eclampsia Trial [Recruiting]
Eclampsia is a major cause of perinatal morbidity and mortality. The pathophysiology is not
known but magnetic resonance imaging (MRI) and Doppler data suggest that overperfusion of
the cerebral tissues is a major etiologic factor. Hypertensive encephalopathy from
overperfusion, and vascular damage from excessive arterial pressure (cerebral barotrauma)
are believed to lead to vasogenic and cytotoxic cerebral edema, with resultant neuronal
anomalies, seizure activity and cerebral bleeding if left unchecked. Doppler data have shown
that cerebral perfusion pressure (CPP) is abnormally increased in severe preeclampsia and
that autoregulation of the middle cerebral artery is affected by this condition leading to
increased CPP. Magnesium sulfate (MgSO4) is the most widely accepted eclampsia treatment and
prophylactic agent, and it has been used in the USA since the 1950's. Despite widespread
use, its mechanism of action is unknown. MgSO4 is given intravenously or intramuscularly and
requires specialized nursing training and monitoring to minimize toxicity from respiratory
and cardiac depression. Labetalol, a combined alpha and beta blocker, has been used for many
years to safely treat hypertension in preeclamptic women, and is now known to reduce CPP in
women with preeclampsia. In the United Kingdom labetalol was for many years used as the sole
agent in treating preeclampsia, and the rate of seizure was no different to that reported in
the USA with MgSO4. Since labetalol can be administered orally, is economical, has low
toxicity potential, does not require specialized training to administer or monitor, and
decreases CPP, it may be an ideal agent for controlling blood pressure (BP) and decreasing
the incidence of eclampsia in women with preeclampsia. The current study is a multicenter,
randomized, controlled trial to compare the anti-seizure effect of parenteral MgSO4 versus
oral labetalol in hypertensive pregnant women who are eligible for MgSO4 therapy. The
primary outcome measure is eclampsia, and the secondary outcome measures include blood
pressure control, and relevant antenatal, intrapartum, and postnatal maternal and
fetal/neonatal parameters including adverse effects and complications. Inclusion criteria
are deliberately broad in order to make the study clinically relevant. Hypertensive pregnant
women, in whom the decision for delivery has been made, will be enrolled after written,
informed consent. Patients will be randomized to receive MgSO4 therapy as given in their
institution, versus oral labetalol (200mg/q6 hours), from enrollment in the study until 24
hours post delivery. There will be 4000 patients in each arm of the study and analysis will
be by intention-to-treat. The study is powered to show both therapeutic superiority as well
as clinical equivalence. This study has the potential to change the way preeclampsia is
managed, and will represent a major advance in terms of the availability and safety of
prophylactic therapy, especially in developing nations where MgSO4 is underutilized due to
Nicardipine Versus Labetalol During Intubation [Recruiting]
The aim of this study was to compare the efficacy of nicardipine and labetalol in
attenuation of cardiovascular responses to endotracheal intubation.
Evaluation of IV Cardene(Nicardipine)and Labetalol Use in the Emergency Department [Recruiting]
Effects of Labetalol on Human Cocaine Use - 8 [Completed]
Page last updated: 2011-12-09